Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers

Clinics in Dermatology

Volumn 14, Issue 5, 1996, Pages 489-495

  Bahar, Kamal ^a   Dowlati, Yahya ^b   Shidani, Babak ^b   Alimohammadian, Mohammad Hossein ^b   Khamesipour, Ali ^b   Ehsasi, Siemin ^b   Hashemi Fesharki, Reza ^b   Ale Agha, Saeed ^b   Modabber, Farrokh ^b  

^a Bahar Medical Laboratory   (Iran)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INACTIVATED VACCINE; LEISHMANIA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LEISHMANIA MAJOR; LEISHMANIASIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030248707     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0738-081X(96)00071-5     Document Type: Article

References (17)

1. 1. Rachamim N, Jaffe CL. Pure protein from L. donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol 1993;150:2322-31.
2. 2. Connell ND, Medina-Acosta E, McMaster RW, et al. Effective immunization against cutaneous leishmaniasis with recombinant bacilli Calmette-Guerin expressing the Leishmania surface protease gp63. Proc Natl Acad Sci USA 1993;90:11473-7.
3. 3. Tropical Disease Research: Twelfth programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Geneva: WHO, 1995:135-46.
4. 4. Antunes CMF, Mayrink W, Magalhaes PA, et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986;15:572-80.
5. 5. Castes M, Trujillo D, Calcagno M, et al. Response Th1-Th2 in human American cutaneous leishmaniasis: Its possible relevance for design of a vaccine. Mem Inst Oswaldo Cruz 1993;88:42-3.
6. 6. Bahar K, Shidani B, Hashemi Fesharki R, et al. Responses and reactions to L. major vaccination. Proceeding of meeting on vaccines against leishmaniasis. Belo Horizonte, University of Minas Gerais and UNDP/World Bank/ WHO Special Program for Research and Training in Tropical Diseases, 10-11 September 1990:20-1.
7. 7. Bahar K, Ehsasi S, Dowlati Y, et al. Overview of human vaccine studies using killed L. major, in session of "Immunology & molecular biology of leishmaniasis"; XIII In" ternational Congress for Tropical Medicine & Malaria. Jomtien, Pattaya, Thailand, 29 November-4 December 1992.
8. 8. Bahar K, Ehsasi S, Dowlati Y, et al. Biological activities of Leishmania extracts. XIII International Congress for Tropi-cal Medicine & Malaria. Jomtien, Pattaya, Thailand, 29 November-4 December 1992.
9. 9. Hashemi-Fesharki R, Ale-Agha S, Ahourai P, et al. Vaccine preparation and quality control of killed Leishmania major. Arch Inst Razi 1992;42/43:39-50.
10. 10. Bradford M. A rapid and sensitive method for quantisation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
11. 11. Savory J, Hammond JE. Measurement of proteins in biologic fluids. In: Sonnewirth AC, Jarett L, editors. Gradwohl's clinical laboratory method and diagnosis, 8th ed. St. Louis: Mosby, 1990:258-9.
12. 12. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with Polin phenol reagent. J Biol Chem 1951; 193:265-75.
13. 13. Alimohammadian MS, Hakimi H, Nikseresht M. The preparation and evaluation of reference leishmanin from Leishmania major for use in man for diagnostic and experimental purposes. MJIRI 1993;7:23-8.
14. 14. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975;293:501-2.
15. 15. Badaro R, Pedral-Sampaio D, Johnson WD, et al. Evaluation of the stability of a soluble intradermal skin test antigen preparation in American visceral leishmaniasis. Trans R Soc Trop Med Hyg 1990;84:226-7.
16. 16. Bretcher PA, Wei G, Menon JN, et al. Establishment of stable, cell-mediated immunity that makes 'susceptible' mice resistant to Leishmania major. Science 1992;257:539-42.
17. 17. Mayrink W, Williams P, Da Costa CA, et al. An experimental vaccine against American dermal leishmaniasis: Experience in the State of Espirito Santo, Brazil. Ann Trop Med Parasitol 1985;79:259-69.